SCHEMBL3785235

SCHEMBL3785235

CCn1nc(N(C)c2ccccc2)c2c(N)ncnc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 3/20 0.51
▸ PRKDC P78527 3/20 0.51
▸ KDR P35968 3/20 0.44
▸ RET P07949 2/20 0.44
▸ FYN P06241 5/20 0.44
▸ EGFR P00533 5/20 0.42
▸ SRC P12931 5/20 0.42
▸ ABL1 P00519 2/20 0.42
▸ PIK3CA P42336 2/20 0.42
▸ PIK3CB P42338 2/20 0.42
▸ PIK3CG P48736 2/20 0.42
▸ HCK P08631 1/20 0.42
▸ MTOR P42345 1/20 0.42
▸ EPHB4 P54760 1/20 0.42
▸ PI4KB Q9UBF8 1/20 0.42
▸ MAP2K5 Q13163 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13020102 0.86 EGFR (0.47) PIK3CDPRKDCKDRRETFYN
SCHEMBL13063879 0.80 SRC (0.61) PIK3CDPRKDCKDRRETFYN
SCHEMBL15826968 0.76 PIK3CD (0.73) PIK3CDPRKDCKDRRETFYN
SCHEMBL13020099 0.76 BTK (0.52) PIK3CDPRKDCKDRRETEGFR
SCHEMBL3787263 0.73 PIK3CD (0.52) PIK3CDPRKDCKDRRETFYN
SCHEMBL13064034 0.73 PIK3CD (0.55) PIK3CDPRKDCKDRRETFYN
SCHEMBL10261498 0.73 PIK3CD (0.53) PIK3CDPRKDCKDRRETFYN
SCHEMBL15826969 0.70 PIK3CD (0.51) PIK3CDPRKDCKDRRETEGFR
SCHEMBL868744 0.70 PIK3CD (0.51) PIK3CDPRKDCKDRRETFYN
SCHEMBL27943334 0.70 LRRK2 (0.43) PIK3CDPRKDCKDRRETFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 — — US disclosed
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 — — US disclosed
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING RAB1A, COPB1, GOLT1B PIK3CD 2217/4885PRKDC 1498/4885KDR 4598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback